Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,300 yen, down from 1,600 yen. The downgrade reflects eliminating the estimated contribution from a peptide that Bristol Myers Squibb was developing in Phase 1 trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PPTDF: